LabCorp Publishes Largest Study to Date on Prenatal Cell-Free DNA Screenings in Multifetal Pregnancies

Study of nearly 30,000 cases finds that non-invasive cfDNA screening for fetal aneuploidy in pregnancies with twins, triplets, and higher-order multiples meets or exceeds performance of singleton pregnancy screening   BURLINGTON, N.C. --(BUSINESS WIRE)--Sep.

LabCorp to Announce Third Quarter Financial Results on October 24, 2019

  BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 24, 2019-- LabCorp® (NYSE: LH) will release its third quarter of 2019 financial results before the market opens on Thursday, Oct. 24, 2019 , followed by a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results.

Identification of two novel deletions with breakpoints located in Exon 11 in the BRCA2 gene

Confirmed maternal neoplasms detected via informaSeq® non-invasive prenatal screening

Population carrier screening decisions for cystic fibrosis and spinal muscular atrophy: A retrospective study of >300,000 genetic counseling patients

Decisions regarding prenatal diagnosis following abnormal cell-free DNA results

A more efficient approach for prenatal genetic counseling in a large obstetric setting

Elevated TGFα levels in chronic mylogenous leukemia (CML) patient plasma measured by a highly sensitive single molecule array immunoassay

Prenatal and postnatal SNP microarray analysis and parental follow-up of 16q24.1 deletions/duplications that include the FOXF1 gene